Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$1.34 USD
+0.01 (0.75%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.33 -0.01 (-0.75%) 5:42 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.34 USD
+0.01 (0.75%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.33 -0.01 (-0.75%) 5:42 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Zacks News
Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Therapeutics (AKBA) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 40.26% and 33.88%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Endo Recalls 2 Lots of Robaxin Tablets Due to Labeling Error
by Zacks Equity Research
Endo International (ENDP) recalls two lots of Robaxin 750mg Tablets due to wrong dosing information on the label.
Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag
by Zacks Equity Research
Keryx (KERX) posts wider-than-expected loss in Q2. Moreover, revenues miss the mark.
Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -15.38% and 0.09%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More
by Zacks Equity Research
Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.
Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall
by Zacks Equity Research
Keryx Biopharmaceuticals (KERX) enters into a definitive merger agreement with Akebia Therapeutics, Inc. under which the companies will combine in an all-stock merger.
Market Has Not Yet Noticed Potential in Akebia Therapeutics (AKBA); Have You?
by Zacks Equity Research
Akebia Therapeutics (AKBA) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.
Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI)
by Zacks Equity Research
Aerie Pharmaceuticals (AERI) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Concert Pharmaceuticals (CNCE) Soars: Stock Adds 5.7% in Session
by Zacks Equity Research
Concert Pharmaceuticals (CNCE) saw its shares rise nearly 6% on the day.
GlycoMimetics (GLYC) Jumps: Stock Rises 11.9%
by Zacks Equity Research
GlycoMimetics (GLYC) was a big mover last session, as the company saw its shares nearly 10%on the day amid huge volumes.
BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA
by Zacks Equity Research
The FDA currently shows no intent to hold an AdCom to discuss the BLA for BioMarin's (BMRN) pipeline candidate, pegvaliase.
GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down
by Zacks Equity Research
GTx (GTXI) posts positive data from a phase II study of enobosarm for treating women with stress urinary incontinence. However, shares dip possibly with the release falling below market estimates.
Ultragenyx's Burosumab Positive in Phase II for XLH and TIO
by Zacks Equity Research
Ultragenyx's (RARE) burosumab passes the test with positive data from two phase II studies. The candidate gets evaluated for X-linked hypophosphatemia and tumor-induced osteomalacia.
BioMarin Presents Interim Data on BMN 250 from Phase I/II
by Zacks Equity Research
BioMarin's (BMRN) interim data from a current dose escalation phase I/II study on BMN 250 shows improvement signs in cognitive Development Quotient.
Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge
by Zacks Equity Research
Akebia Therapeutics (AKBA), could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.
FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down
by Zacks Equity Research
Acorda (ACOR) receives a refusal to file (RTF) letter from the FDA in connection with Inbrija's NDA.
Strength Seen in Catalent (CTLT): Stock Soars 13.9%
by Zacks Equity Research
Catalent (CTLT) was a big mover last session, as the company saw its shares rise almost 14% on the day amid huge volumes.
Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8%
by Zacks Equity Research
Akebia Therapeutics, Inc. (AKBA) shares rose almost 6% in the last trading session.
KalVista Pharmaceuticals (KALV) in Focus: Stock Jumps 6%
by Zacks Equity Research
KalVista Pharmaceuticals, Inc. (KALV) saw its shares rise 6% in the last trading session.
Advanced Accelerator (AAAP) Catches Eye: Stock Jumps 5.4%
by Zacks Equity Research
Advanced Accelerator Applications S.A. (AAAP) moved big last session, as its shares rose over 5% on the day.
Concordia International (CXRX) Looks Good: Stock Jumps 11.4%
by Zacks Equity Research
Concordia International Corp. (CXRX) shares rose over 11% in the last trading session.
Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge
by Zacks Equity Research
Akebia Therapeutics (AKBA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision.